Volanesorsen: First Global Approval-Reference-Cited by-同舟云学术

Volanesorsen: First Global Approval

Published:2019-07-12 Issue:12 Volume:79 Page:1349-1354
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Paik Julia,Duggan Sean

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01168-z.pdf

Reference12 articles.

1. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–6.

2. Rocha NA, East C, Zhang J, et al. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep. 2017;19(12):62.

3. Hanssen R, Gouni-Berthold I. Antisense oligonucleotides for the treatment of hypertriglyceridemia and hyperlipoproteinemia. Curr Pharmacol Rep. 2017;3(6):458–68.

4. Akcea Therapeutics. Akcea and Ionis announce approval of WAYLIVRA® (volanesorsen) in the European Union [media release]. 7 May 2019. http://www.akceatx.com .

5. European Medicines Agency. Volanesorsen: EU summary of product characteristics. 2019. https://www.waylivra.eu/wp-content/uploads/2019/05/WAYLIVRA-SmPC.pdf . Accessed 4 July 2019.

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of classical Machine Learning-based algorithms to predict Triplex Forming Oligonucleotides;Computational and Structural Biotechnology Reports;2024-12

2. The Role of RNA Splicing in Liver Function and Disease: A Focus on Metabolic Dysfunction-Associated Steatotic Liver Disease;Genes;2024-09-08

3. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives;International Journal of Molecular Sciences;2024-09-08

4. Assessment of Platelet Aggregation and Thrombin Generation in Patients with Familial Chylomicronemia Syndrome Treated with Volanesorsen: A Cross-Sectional Study;Biomedicines;2024-09-04

5. Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing;Molecular Therapy - Nucleic Acids;2024-09